Delayed
BME
01:37:35 02/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
2.49
EUR
|
0.00%
|
|
-1.58%
|
+10.67%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
147.8
|
190.9
|
335.4
|
250.8
|
170.1
|
177.3
|
Enterprise Value (EV)
1 |
165.5
|
237.5
|
381.3
|
312.9
|
224.9
|
225.2
|
P/E ratio
|
16.1
x
|
36.3
x
|
57
x
|
49.2
x
|
21.9
x
|
18.8
x
|
Yield
|
-
|
-
|
1.03%
|
1.23%
|
1.83%
|
-
|
Capitalization / Revenue
|
0.8
x
|
0.93
x
|
1.44
x
|
1.05
x
|
0.62
x
|
0.56
x
|
EV / Revenue
|
0.89
x
|
1.15
x
|
1.63
x
|
1.3
x
|
0.82
x
|
0.71
x
|
EV / EBITDA
|
10.8
x
|
11.4
x
|
18.8
x
|
15.4
x
|
9.97
x
|
7.96
x
|
EV / FCF
|
-21.6
x
|
-44.2
x
|
29.3
x
|
-18.1
x
|
25
x
|
49.2
x
|
FCF Yield
|
-4.62%
|
-2.26%
|
3.42%
|
-5.52%
|
3.99%
|
2.03%
|
Price to Book
|
0.99
x
|
1.07
x
|
1.81
x
|
1.33
x
|
0.87
x
|
0.87
x
|
Nbr of stocks (in thousands)
|
64,837
|
75,770
|
76,412
|
76,935
|
77,694
|
78,802
|
Reference price
2 |
2.280
|
2.520
|
4.390
|
3.260
|
2.190
|
2.250
|
Announcement Date
|
01/03/19
|
02/03/20
|
26/02/21
|
28/02/22
|
28/02/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
185.3
|
205.8
|
233.8
|
239.9
|
274.2
|
318
|
EBITDA
1 |
15.29
|
20.79
|
20.32
|
20.36
|
22.56
|
28.3
|
EBIT
1 |
8.788
|
8.843
|
9.566
|
9.276
|
9.373
|
11.99
|
Operating Margin
|
4.74%
|
4.3%
|
4.09%
|
3.87%
|
3.42%
|
3.77%
|
Earnings before Tax (EBT)
1 |
9.483
|
5.303
|
6.426
|
5.793
|
8.764
|
10.5
|
Net income
1 |
9.266
|
4.942
|
5.672
|
5.092
|
8.107
|
9.407
|
Net margin
|
5%
|
2.4%
|
2.43%
|
2.12%
|
2.96%
|
2.96%
|
EPS
2 |
0.1419
|
0.0693
|
0.0770
|
0.0662
|
0.1000
|
0.1194
|
Free Cash Flow
1 |
-7.652
|
-5.373
|
13.02
|
-17.28
|
8.98
|
4.577
|
FCF margin
|
-4.13%
|
-2.61%
|
5.57%
|
-7.2%
|
3.27%
|
1.44%
|
FCF Conversion (EBITDA)
|
-
|
-
|
64.09%
|
-
|
39.8%
|
16.17%
|
FCF Conversion (Net income)
|
-
|
-
|
229.6%
|
-
|
110.77%
|
48.65%
|
Dividend per Share
|
-
|
-
|
0.0450
|
0.0400
|
0.0400
|
-
|
Announcement Date
|
01/03/19
|
02/03/20
|
26/02/21
|
28/02/22
|
28/02/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
17.6
|
46.6
|
45.9
|
62.1
|
54.8
|
47.9
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.154
x
|
2.24
x
|
2.257
x
|
3.048
x
|
2.427
x
|
1.693
x
|
Free Cash Flow
1 |
-7.65
|
-5.37
|
13
|
-17.3
|
8.98
|
4.58
|
ROE (net income / shareholders' equity)
|
6.35%
|
3.01%
|
3.13%
|
2.72%
|
4.23%
|
4.71%
|
ROA (Net income/ Total Assets)
|
2.6%
|
2.07%
|
1.9%
|
1.81%
|
1.81%
|
2.3%
|
Assets
1 |
356.8
|
238.4
|
299.2
|
282
|
447.1
|
409
|
Book Value Per Share
2 |
2.310
|
2.350
|
2.420
|
2.460
|
2.510
|
2.590
|
Cash Flow per Share
2 |
0.1300
|
0.1300
|
0.1500
|
0.0700
|
0.0800
|
0.0700
|
Capex
1 |
15.9
|
5.85
|
4.21
|
19.2
|
10.9
|
12.5
|
Capex / Sales
|
8.56%
|
2.84%
|
1.8%
|
8.01%
|
3.99%
|
3.92%
|
Announcement Date
|
01/03/19
|
02/03/20
|
26/02/21
|
28/02/22
|
28/02/23
|
29/02/24
|
|
1st Jan change
|
Capi.
|
---|
| +10.67% | 210M | | +33.25% | 699B | | +25.58% | 571B | | -3.55% | 364B | | +18.16% | 326B | | +4.36% | 286B | | +14.92% | 236B | | +5.02% | 198B | | -10.47% | 194B | | -3.69% | 149B |
Other Pharmaceuticals
|